Modulation of the tumor cell phenotype by IFN-γ results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes

Journal of Immunology

Volumn 180, Issue 6, 2008, Pages 3766-3774

  Hallermalm, Kristian ^a   Seki, Kazutake ^a   De Geer, Anna ^a   Motyka, Bruce ^b   Bleackley, R Chris ^b   Jager, Martine J ^c   Froelich, Christopher J ^d   Kiessling, Rolf ^a   Levitsky, Victor ^a   Levitskaya, Jelena ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANZYME B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; GRANZYME; TUMOR MARKER;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; MELANOMA CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TUMOR CELL; UPREGULATION; UVEA MELANOMA; BLOOD; CELL CLONE; CELL MEMBRANE PERMEABILITY; CYTOTOXICITY; DOWN REGULATION; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOPHENOTYPING; INNATE IMMUNITY; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UVEA TUMOR;

CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; GRANZYMES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, NATURAL; IMMUNOPHENOTYPING; INTERFERON TYPE II; MELANOMA; PERFORIN; PROGNOSIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UVEAL NEOPLASMS;

EID: 44849098983     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.6.3766     Document Type: Article

References (57)

1. Farrar, M. A., and R. D. Schreiber. 1993. The molecular cell biology of interferon-γ and its receptor. Annu. Rev. Immunol. 11: 571-611.
2. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15: 749-795.
3. Dupuis, S., R. Doffinger, C. Picard, C. Fieschi, F. Altare, E. Jouanguy, L. Abel, and J. L. Casanova. 2000. Human interferon-γ-mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion. Immunol. Rev. 178: 129-137.
4. Willimsky, G., and T. Blankenstein. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437: 141-146.
5. Burnet, F. M. 1971. Immunological surveillance in neoplasia. Transplant Rev. 7: 3-25.
6. Dighe, A. S., E. Richards, L. J. Old, and R. D. Schreiber. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1: 447-456.
7. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95: 7556-7561.
8. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
9. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
10. Garrido, F., and I. Algarra. 2001. MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res. 83: 117-158.
11. Woll, E., A. Bedikian, and S. S. Legha. 1999. Uveal melanoma: natural history and treatment options for metastatic disease. Melonoma Res. 9: 575-581.
12. Likhvantseva, V. G., O. S. Slepova, and A. F. Brovkina. 1999. [Interferon status of patients with uveal melanoma]. Vestn Oftalmol. 115: 35-37.
13. Filer, R. S., J. C. Song, D. H. Char, and S. Kaleta-Michaels. 1993. [Cytokines in uveal melanoma. Original title: uveal melanoma cytokines]. Klin Monatsbl Augenheilkd. 202: 174-179.
14. Blom, D. J., G. P. Luyten, C. Mooy, S. Kerkvliet, A. H. Zwinderman, and M. J. Jager. 1997. Human leukocyte antigen class I expression: marker of poor prognosis in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 38: 1865-1872.
15. Ericsson, C., S. Seregard, A. Bartolazzi, E. Levitskaya, S. Ferrone, R. Kiessling, and O. Larsson. 2001. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42: 2153-2156.
16. Alexander, J., J. A. Payne, R. Murray, J. A. Frelinger, and P. Cresswell. 1989. Differential transport requirements of HLA and H-2 class I glycoproteins. Immunogenetics 29: 380-388.
17. Salter, R. D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 5: 943-949.
18. Levitsky, V., P. O. de Campos-Lima, T. Frisan, and M. G. Masucci. 1998. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J. Immunol. 161: 594-601.
19. Motyka, B., G. Korbutt, M. J. Pinkoski, J. A. Heibein, A. Caputo, M. Hobman, M. Barry, I. Shostak, T. Sawchuk, C. F. Holmes, et al. 2000. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103: 491-500.
20. Froelich, C. J., J. Turbov, and W. Hanna. 1996. Human perforin: rapid enrichment by immobilized metal affinity chromatography (IMAC) for whole cell cytotoxicity assays. Biochem. Biophys. Res. Commun. 229: 44-49.
21. Purbhoo, M. A., D. J. Irvine, J. B. Huppa, and M. M. Davis. 2004. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5: 524-530.
22. Torsteinsdottir, S., M. G. Masucci, B. Ehlin-Henriksson, C. Brautbar, H. Ben Bassat, G. Klein, and E. Klein. 1986. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc. Natl. Acad. Sci. USA 83: 5620-5624.
23. Hallermalm, K., K. Seki, C. Wei, C. Castelli, L. Rivoltini, R. Kiessling, and J. Levitskaya. 2001. Tumor necrosis factor-α induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 98: 1108-1115.
24. De Geer, A., R. Kiessling, V. Levitsky, and J. Levitskaya. 2006. Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion. J. Immunol. 177: 7540-7550.
25. Fruh, K., and Y. Yang. 1999. Antigen presentation by MHC class I and its regulation by interferon γ. Curr. Opin. Immunol. 11: 76-81.
26. Sherman, L. A., and S. Chattopadhyay. 1993. The molecular basis of allorecognition. Annu. Rev. Immunol. 11: 385-402.
27. Morel, S., F. Levy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A. L. Peitrequin, B. Monsarrat, R. Van Velthoven, J. C. Cerottini, T. Boon, et al. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12: 107-117.
28. Basler, M., N. Youhnovski, M. Van Den Broek, M. Przybylski, and M. Groettrup. 2004. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J. Immunol. 173: 3925-3934.
29. Chapiro, J., S. Claverol, F. Piette, W. Ma, V. Stroobant, B. Guillaume, J. E. Gairin, S. Morel, O. Burlet-Schiltz, B. Monsarrat, T. Boon, and B. J. Van den Eynde. 2006. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 176: 1053-1061.
30. Repp, A. C., E. S. Mayhew, S. Apte, and J. Y. Niederkorn. 2000. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J. Immunol. 165: 710-715.
31. Borrego, F., J. Kabat, D. K. Kim, L. Lieto, K. Maasho, J. Pena, R. Solana, and J. E. Coligan. 2002. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol. Immunol. 38: 637-660.
32. Hurks, H. M., M. M. Valter, L. Wilson, I. Hilgert, P. J. van den Elsen, and M. J. Jager. 2001. Uveal melanoma: no expression of HLA-G. Invest. Ophthalmol. Vis. Sci. 42: 3081-3084.
33. Brooks, A. G., J. C. Boyington, and P. D. Sun. 2000. Natural killer cell recognition of HLA class I molecules. Rev. Immunogenet. 2: 433-448.
34. Shresta, S., C. T. Pham, D. A. Thomas, T. A. Graubert, and T. J. Ley. 1998. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10: 581-587.
35. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182: 1777-1783.
36. Raja, S. M., S. S. Metkar, and C. J. Froelich. 2003. Cytotoxic granule-mediated apoptosis: unraveling the complex mechanism. Curr. Opin. Immunol. 15: 528-532.
37. Darmon, A. J., and R. C. Bleackley. 1998. Proteases and cell-mediated cytotoxicity. Crit. Rev. Immunol. 18: 255-273.
38. Sutton, V. R., J. E. Davis, M. Cancilla, R. W. Johnstone, A. A. Ruefli, K. Sedelies, K. A. Browne, and J. A. Trapani. 2000. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 192: 1403-1414.
39. Verbik, D. J., T. G. Murray, J. M. Tran, and B. R. Ksander. 1997. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int. J. Cancer 73: 470-478.
40. Metkar, S. S., B. Wang, M. Aguilar-Santelises, S. M. Raja, L. Uhlin-Hansen, E. Podack, J. A. Trapani, and C. J. Froelich. 2002. Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 16: 417-428.
41. Veugelers, K., B. Motyka, C. Frantz, I. Shostak, T. Sawchuk, and R. C. Bleackley. 2004. The granzyme B-serglycin complex from cytotoxic granules requires dynamin for endocytosis. Blood 103: 3845-3853.
42. Veugelers, K., B. Motyka, I. S. Goping, I. Shostak, T. Sawchuk, and R. C. Bleackley. 2006. Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate. Mol. Biol. Cell 17: 623-633.
43. Trapani, J. A., V. R. Sutton, K. Y. Thia, Y. Q. Li, C. J. Froelich, D. A. Jans, M. S. Sandrin, and K. A. Browne. 2003. A clathrin/dynamin- and mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death. J. Cell Biol. 160: 223-233.
44. Dressel, R., S. M. Raja, S. Honing, T. Seidler, C. J. Froelich, K. von Figura, and E. Gunther. 2004. Granzyme-mediated cytotoxicity does not involve the mannose 6-phosphate receptors on target cells. J. Biol. Chem. 279: 20200-20210.
45. Gross, C., W. Koelch, A. DeMaio, N. Arispe, and G. Multhoff. 2003. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J. Biol. Chem. 278: 41173-41181.
46. Toyama-Sorimachi, N., H. Sorimachi, Y. Tobita, F. Kitamura, H. Yagita, K. Suzuki, and M. Miyasaka. 1995. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan: possible involvement in lymphoid cell adherence and activation. J. Biol. Chem. 270: 7437-7444.
47. Sharma, B., and R. V. Iozzo. 1998. Transcriptional silencing of perlecan gene expression by interferon-γ. J. Biol. Chem. 273: 4642-4646.
48. Raja, S. M., S. S. Metkar, S. Honing, B. Wang, W. A. Russin, N. H. Pipalia, C. Menaa, M. Belting, X. Cao, R. Dressel, and C. J. Froelich. 2005. A novel mechanism for protein delivery: granzyme B undergoes electrostatic exchange from serglycin to target cells. J. Biol. Chem. 280: 20752-20761.
49. Bene, L., A. Bodnar, S. Damjanovich, G. Vamosi, Z. Bacso, J. Aradi, A. Berta, and J. Damjanovich. 2004. Membrane topography of HLA I, HLA II, and ICAM-1 is affected by IFN-γ in lipid rafts of uveal melanomas. Biochem. Biophys. Res. Commun. 322: 678-683.
50. + cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42: 1414-1421.
51. Niederkorn, J. Y. 1997. Immunoregulation of intraocular tumours. Eye 11: 249-254.
52. Folberg, R., M. J. Hendrix, and A. J. Maniotis. 2000. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156: 361-381.
53. Medema, J. P., J. de Jong, L. T. Peltenburg, E. M. Verdegaal, A. Gorter, S. A. Bres, K. L. Franken, M. Hahne, J. P. Albar, C. J. Melief, and R. Offringa. 2001. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl. Acad. Sci. USA 98: 11515-11520.
54. Stout-Delgado, H. W., Y. Getachew, T. E. Rogers, B. C. Miller, and D. L. Thiele. 2007. The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B-dependent hepatotoxicity. Hepatology 46: 1530-1540.
55. Huber, C., N. Bobek, J. Kuball, S. Thaler, S. Hoffarth, C. Huber, M. Theobald, and M. Schuler. 2005. Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo. Cell Death Differ. 12: 317-325.
56. Marques, C. A., P. S. Hahnel, C. Wolfel, S. Thaler, C. Huber, M. Theobald, and M. Schuler. 2007. An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression. Blood 111: 1413-1419.
57. Malmberg, K. J., V. Levitsky, H. Norell, C. T. de Matos, M. Carlsten, K. Schedvins, H. Rabbani, A. Moretta, K. Soderstrom, J. Levitskaya, and R. Kiessling. 2002. IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 110: 1515-1523.